A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Trials

Background:

• Epithelial ovarian cancer (EOC) is a leading cause of gynecologic cancer mortality.
• Optimizing consolidation chemotherapy after first-line treatment is crucial for improving patient outcomes.
• Previous studies have explored platinum-based regimens for ovarian cancer consolidation.

Purpose of the Study:

• To evaluate the efficacy of consolidation chemotherapy with Cisplatin and 5-Fluorouracil (FU) in improving disease-free survival (DFS) and overall survival (OS) in EOC patients.
• To compare outcomes between patients receiving additional chemotherapy and those in an observation (nihil) group.

Main Methods:

• A multicenter randomized study involving 122 EOC patients in complete remission after first-line chemotherapy.
• One arm received 3 cycles of 5-Fluorouracil (FU) plus Cisplatin consolidation chemotherapy.
• The control arm (nihil group) received no further treatment.

Main Results:

• No significant differences in median overall survival (95 vs. 96 months) or median disease-free survival (66 vs. 73 months) were observed between the FU+Cisplatin and nihil groups.
• While peritoneal relapse rates were higher in the FU+Cisplatin arm (25% vs. 16.4%), overall and disease-free survival remained similar.
• Fewer second neoplasms were observed in the Cisplatin arm (1 vs. 6), though deaths were attributed to these, not ovarian cancer progression.

Conclusions:

• Consolidation chemotherapy with Cisplatin and 5-Fluorouracil (FU) does not enhance overall survival or disease-free survival in epithelial ovarian cancer patients.
• The addition of platinum plus FU treatment after standard first-line chemotherapy does not provide a survival benefit.
• Further investigation into optimal consolidation strategies for EOC is warranted.